Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01109433 · ClinicalTrials.gov registry record
Immunogenetic Mechanisms in Behcet's Disease
A clinical trial, sponsored by National Eye Institute (NEI).
- Terminated
- Registry status
- 25
- Enrollment target
NCT01109433: Clinical Trial study, sponsored by National Eye Institute (NEI).
NCT01109433 is a clinical trial that was terminated before completion, run by National Eye Institute (NEI). The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01109433 was terminated before completion, sponsored by National Eye Institute (NEI).
- TERMINATED
- Registry status
- 25 participants
- Enrollment target
Study Summary
Background: \- Uveitis, the inflammation of the interior of the eye, is responsible for numerous new cases of legal blindness every year. Uveitis can be caused by Beh(SqrRoot)(Beta)et s disease (BD), a chronic inflammatory disorder that can affect the eye, mucous membranes, and other body organs such as the joints, intestinal tract, blood vessels, and central nervous system. Objectives: The purpose of this study is to see how genes affect Beh(SqrRoot)(Beta)et s disease and if there are differences in Beh(SqrRoot)(Beta)et s disease among people of different backgrounds. Eligibility: * Individuals who have a diagnosis of BD and are enrolled in another NIH study. * Individuals who are willing to donate blood for the purposes of this research study and who are willing to have their blood stored for possible future/other research purposes. Design: * As part of the study, blood samples will be drawn from participants when an exacerbation in disease activity occurs and before and after any significant change in treatment for BD. * No treatments will be provided in this study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2010-04-15 |
| Est. Completion | 2018-12-17 |
Why NCT01109433 stopped before completion
NCT01109433 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01109433 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01109433 about?
NCT01109433 is a clinical study titled "Immunogenetic Mechanisms in Behcet's Disease". Background: \- Uveitis, the inflammation of the interior of the eye, is responsible for numerous new cases of legal blindness every year. Uveitis can be caused by Beh(SqrRoot)(Beta)et s disease (BD), a chronic inflammatory disorder that can affect the eye, mucous membranes, and other body organs su...
What is the current status of trial NCT01109433?
This trial is currently terminated. The enrollment target is 25 participants. The study started on 2010-04-15. Estimated completion is 2018-12-17.
Who is sponsoring clinical trial NCT01109433?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI